

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

CD38-PE, human

RRID:AB_2660381

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-907, RRID:AB_2660381

Antibody Information

URL: http://antibodyregistry.org/AB_2660381

Proper Citation: Miltenyi Biotec Cat# 130-098-907, RRID:AB_2660381

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 7-2018; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-989. (RRID:AB_2733812).

Antibody Name: CD38-PE, human

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: IB6

Antibody ID: AB_2660381

Vendor: Miltenyi Biotec

Catalog Number: 130-098-907

Record Creation Time: 20231110T034358+0000

Record Last Update: 20260829T111257+0000

Ratings and Alerts

No rating or validation information has been found for CD38-PE, human.

Warning: Discontinued: 2021

Discontinued: 7-2018; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-989. (RRID:AB_2733812).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu C, et al. (2022) Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell metabolism, 34(6), 818.